Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease 4, Autosomal Dominant Lewy Body

Explore clinical trials studying Parkinson Disease 4, Autosomal Dominant Lewy Body. Study availability and eligibility vary by location and protocol.

229 public trials 34 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body trial results

Completed

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

NCT02027961

Conditions
Melanoma, Neoplasm Metastasis, Neoplasms, +14 more
Locations
  • Research Site Scottsdale, Arizona, United States
  • Research Site Los Angeles, California, United States
  • Research Site San Francisco, California, United States
  • Research Site Miami Beach, Florida, United States
View Trial Details
Completed

FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)

NCT03170063

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +7 more
Locations
  • Rush University Medical Center Chicago, Illinois, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Oregon Health and Sciences University Portland, Oregon, United States
  • University of Pennsylvania Philadelphia, Pennsylvania, United States
View Trial Details
Completed

Systemic Synuclein Sampling Study (S4)

NCT02572713

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +8 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic Arizona Scottsdale, Arizona, United States
  • Institute for Neurodegenerative Disorders New Haven, Connecticut, United States
  • Oregon Health & Science University Portland, Oregon, United States
View Trial Details
Terminated

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

NCT04738487

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Boca Raton Regional Hospital ( Site 0004) Boca Raton, Florida, United States
  • Illinois Cancer Care ( Site 0026) Peoria, Illinois, United States
  • Mercy Research - Cancer and Hematology Center ( Site 0032) Springfield, Missouri, United States
  • Mercy Research - David C. Pratt Cancer Center ( Site 0025) St Louis, Missouri, United States
View all 188 locations
View Trial Details
Terminated

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)

NCT04191135

Conditions
Breast Diseases, Breast Neoplasms, Neoplasms, +5 more
Locations
  • Pacific Cancer Care ( Site 0142) Monterey, California, United States
  • UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0138) San Francisco, California, United States
  • John Wayne Cancer Institute ( Site 0111) Santa Monica, California, United States
  • St. Joseph Heritage Healthcare ( Site 0104) Santa Rosa, California, United States
View all 122 locations
View Trial Details
Terminated

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

NCT05665595

Conditions
Melanoma, Neoplasms, Neoplasms by Histologic Type, +10 more
Locations
  • Moores Cancer Center ( Site 0116) La Jolla, California, United States
  • The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131) Los Angeles, California, United States
  • California Pacific Medical Center - Pacific Campus ( Site 0111) San Francisco, California, United States
View all 205 locations
View Trial Details
Terminated

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

NCT04246177

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Arizona Oncology Associates PC- HOPE ( Site 0770) Tucson, Arizona, United States
  • Scripps Clinic Torrey Pines ( Site 0714) La Jolla, California, United States
  • USC Norris Comprehensive Cancer Center ( Site 0717) Los Angeles, California, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0720) Los Angeles, California, United States
View all 205 locations
View Trial Details
Terminated

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

NCT04949256

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +14 more
Locations
  • City of Hope ( Site 0102) Duarte, California, United States
  • MedStar Washington Hospital Center ( Site 0186) Washington D.C., District of Columbia, United States
  • James Graham Brown Cancer Center ( Site 0117) Louisville, Kentucky, United States
  • Norton Cancer Institute ( Site 0116) Louisville, Kentucky, United States
View all 198 locations
View Trial Details

Related conditions